Alnylam Pharmaceuticals, Inc. Market Research Report

Company Overview

Name

Alnylam Pharmaceuticals, Inc.

Mission

Alnylam Pharmaceuticals is dedicated to pioneering RNA interference (RNAi) therapeutics, a revolutionary approach that "silences" the genes causing or contributing to diseases.

Founding and Founders

• Founded: 2002

• Founders: Phillip A. Sharp, PhD (among others), who is also one of the prominent scientists in the company's formation.

Key People

• Yvonne Greenstreet, MBChB, MBA - Chief Executive Officer

• Pushkal Garg, MD - Chief Medical Officer

• Jeff Poulton - Chief Financial Officer

• Robert Hesslein - Chief Legal Officer and Corporate Secretary

• Kelley Boucher - Chief Human Resource Officer

• Timothy Maines - Chief Technical Operations and Quality Officer

• Tolga Tanguler - Chief Commercial Officer

• Piyush Sharma, JD - Chief Ethics & Compliance Officer

• Christine Lindenboom - Chief Corporate Communications Officer

• Evan Lippman - Chief Corporate Development & Strategy Officer

• Kevin Fitzgerald, PhD - Chief Scientific Officer

Headquarters

• Located in Cambridge, Massachusetts, USA.

Number of Employees

• Over 2,000 employees worldwide.

Revenue

• No information is available.

Company Recognition

Alnylam is recognized as the leading company in RNAi therapeutics and has been named a top science employer by Science Magazine for six consecutive years.

Notable Achievements

Alnylam Pharmaceuticals is acknowledged for developing the first five approved RNAi therapeutics, signifying significant contributions to the RNAi therapeutic landscape.

Products

Overview

Alnylam is known for developing RNAi-based therapies targeting genetically defined diseases. Below are their key products:

1. ONPATTRO® (patisiran)

• Description: Treats hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults.

• Key Features: Utilizes lipid nanoparticle formulation to deliver siRNA to liver cells.

2. GIVLAARI® (givosiran)

• Description: Used for the treatment of adults with acute hepatic porphyria (AHP).

• Key Features: Silences ALAS1 mRNA, reducing neurotoxic porphyrin precursors.

3. OXLUMO® (lumasiran)

• Description: Treats primary hyperoxaluria type 1 (PH1) in pediatric and adult patients.

• Key Features: Reduces hepatic production of oxalate by targeting glycolate oxidase.

4. AMVUTTRA® (vutrisiran)

• Description: Designed for the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis) with potential applications in both polyneuropathy and cardiomyopathy.

• Key Features: Focus on enhancing patient experience through reduced dosing frequency.

Recent Developments

Product Launches & Regulatory Progress

• Vutrisiran: Alnylam submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA and a regulatory application to the European Medicines Agency for Vutrisiran, aimed at treating transthyretin amyloidosis with cardiomyopathy.

Clinical Studies and Data Presentations

• Alnylam presented detailed results from the HELIOS-B Phase 3 Study of Vutrisiran at various scientific sessions, showcasing its effectiveness in treating ATTR amyloidosis with cardiomyopathy.

• The company has also consistently disseminated data and research findings from these studies through webcasts and investor presentations.

Partnerships and Collaborations

• No specific partnerships are mentioned, but Alnylam maintains active advocacy, patient access programs, and collaborations in science, emphasizing cross-sector engagements.

Conclusion

Alnylam Pharmaceuticals continues to lead and innovate in the field of RNAi therapeutics, significantly impacting rare and chronic disease treatment landscapes. With a strong pipeline and pioneering spirit, Alnylam aims to expand its influence beyond rare diseases, intending to address prevalent global health challenges.